Guía «Descubriendo los oligonucleótidos terapéuticos»
En la guía exploramos el potencial de los oligonucleótidos en la medicina genética para tratar enfermedades a nivel molecular.
Acess to the download
En la guía exploramos el potencial de los oligonucleótidos en la medicina genética para tratar enfermedades a nivel molecular.
Acess to the downloadOLIGOFASTX aims to combine resources and efforts to create a platform that facilitates and contributes to the generation in Spain of a biopharmaceutical industrial fabric specialised in the development of oligonucleotide-based therapies with RNA as a common thread.
The project seeks long-term collaboration based on complementarity between companies and specialised research centres, covering the entire development cycle of these drugs.
OLIGOFASTX has the ultimate goal of pooling resources and efforts to create a comprehensive platform to facilitate and contribute to the accelerated development of RNA oligonucleotide-based therapies (ASOs, siRNAs and aptamers) in Spain.
The seven constituent entities are specialised in the different activities necessary to complete the oligonucleotide-based drug development cycle, creating the industrial fabric necessary for the emergence of new RNA-based therapies.
As we close 2024 and approach the end of this project, it is time to [...]
In the field of biomedicine, therapeutic oligonucleotides represent a real revolution. These synthetic DNA or [...]
The discovery of ribozymes in the 1980s revealed that RNA can not only store information, [...]
The psychological and emotional implications of living with a rare disease Living with a rare [...]
At this year’ s 2024 Nobel Prizes , the awards in Medicine, Physics and Chemistry [...]
In this article we highlight the importance of science in the fight against cancer, a [...]
The biotechnology industry continues to grow in 2024, remaining a key field in science and [...]
siRNAs represent one of the most revolutionary discoveries in modern biotechnology. They date back to [...]
François Jacob and Jacques Monod transformed our understanding of genetics and laid the foundations of [...]
Oligonucleotides are used in numerous scientific applications, from biomedical research to drug development. In all [...]
Sol Spiegelman was a leading American molecular biologist whose work revolutionised our understanding of nucleic [...]
In recent years, the field of biomedicine has witnessed groundbreaking advances in the development of [...]
In medical research, there are several types of clinical trials that are designed according to [...]
International Biotechnology Day is an opportunity to delve into the incredible advances and potential of [...]
Numerous types of oligonucleotides are synthesised every year for a wide variety of applications in [...]
Molecular biology has revolutionised our understanding of life and opened up a world of possibilities [...]
At OLIGOFASTX, we are dedicated to the development and research of therapeutic oligonucleotides for rare [...]
At OLIGOFASTX, we work to develop therapeutic solutions for patients living with rare diseases. That [...]
In this eighth and final instalment of our #DiscoveringOligonucleotides series, we delve into the process [...]
Biotechnology has expanded our understanding and ability to address human health challenges. However, the path [...]
Clinical trials have been a fundamental pillar in the advancement of medicine and pharmaceutical research. [...]
On International Women’s Day, we join the world in celebrating the achievements and continuing struggle [...]
In a leap year like the current one, where 29 February takes on a special [...]
In this sixth installment of our #DiscoveringOligonucleotides series, we delve into the synthesis and scale-up [...]
Precision medicine has seen extraordinary advances in recent years, driven largely by research into oligonucleotide [...]
In the fifth installment of our #DiscoveringOligonucleotides series, we dive into the preclinical development phase. [...]
Since the pioneering approval of Fomivirsen in 1998, the field of oligonucleotides has undergone a [...]
In this fourth installment of our #DiscoveringOligonucleotides series, we explore a crucial challenge for innovative [...]
In this fourth installment of our #DiscoveringOligonucleotides series, we explore a crucial challenge for innovative [...]
We are coming to the end of this year and through this post we want [...]
Therapeutic oligonucleotides represent a breakthrough technology in genetic medicine, specifically addressing diseases at the molecular [...]
In the field of medicine, orphan drugs have stood out as silent heroes, bringing hope [...]
In this second issue of #DiscoveringOligonucleotides, from the OLIGOFASTX consortium we want to introduce you [...]
Science Week is a unique opportunity to get closer to the fascinating world of science. [...]
At the intersection of technological innovation and healthcare, artificial intelligence (AI) is emerging as a [...]
Therapeutic oligonucleotides have emerged as an exciting and promising class of drugs capable of offering [...]
Small interfering RNA molecules (commonly known by the acronym siRNA small interfering RNA) represent one [...]
From the 1980s and 1990s to the present day, the field of drug delivery has [...]
Advances in science and technology are often the result of the dedication, passion and collaboration [...]
Each year, the world of science and research unites in a celebration of excellence, innovation [...]
Last week, several representatives of the OLIGOFASTX consortium partners attended BioSpain 2023, which has been [...]
The European Biotech Week 2023 (European Biotech Week #EBW2023) with various events in the different [...]
David Bartel (Birmingham, 1958) is a leading researcher in molecular and cell biology who has [...]
The biotechnology industry continues to grow and evolve, a good proof of this is the [...]
The pharmaceutical industry is a constantly growing sector that plays a fundamental role in the [...]
At OLIGOFASTX we are working to achieve solutions that improve the quality of life of [...]
RNA is an essential molecule for life, but its discovery and understanding has been a [...]
In this article, practical advice for parents of children affected by rare diseases will be [...]
RNA Bibliography: a selection of the most influential publications in the field of biotechnology In [...]
The mission of the OLIGOFATSX project is to develop oligonucleotide-based medicines to improve the quality [...]
The OLIGOFASTX team is focused on the development of oligonucleotide-based therapies for certain rare diseases [...]
Clear and accessible science communication is essential to bring research advances closer to the general [...]
Nanotechnology is a field that has revolutionised the pharmaceutical industry. The ability to manipulate materials [...]
Today we talk in our blog about another of the rare diseases that the OLIGOFASTX [...]
The European Week Against Cancer takes place from 25 to 31 May to raise awareness [...]
May 20 marks International Clinical Trials Day, a date designed to highlight the importance of [...]
Technological evolution is increasingly present in all areas of our lives. In today’s article we [...]
In 1961, Marshall Nirenberg and Heinrich Matthaei discovered the genetic code of living beings, which [...]
Today, the OLIGOFASTX team joins in the celebration of the European Patients’ Rights Day, a [...]
Rare diseases (affecting fewer than 1 in 2,000 people) are an emerging global public health [...]
That Artificial Intelligence is coming to our daily lives is nothing new. We have all [...]
Of Spanish origin, the small and idyllic town of Luarca (Asturias) was the birthplace of [...]
Of Spanish origin, the small and idyllic town of Luarca (Asturias) was the birthplace of [...]
We love to share good news from the sector. On this occasion, we share the [...]
One more year, we celebrate #InternationalWomensDay: a day that not only commemorates and pays tribute [...]
Oligofastx is a project born from a need: to offer a therapeutic pathway based on [...]
If there is one word that distinguishes OLIGOFASTX and its philosophy, it is innovation. Thanks [...]
Since 2015, the International Day of Women and Girls in Science has been celebrated every [...]
As it could not be otherwise, from Oligofastx we join in the celebration of the [...]
Leber’s congenital amaurosis (LCA) is an eye disease that primarily affects the retina, the inner [...]
Leber’s congenital amaurosis (LCA) is an eye disease that primarily affects the retina, the inner [...]
The last few years have been a true revolution in terms of discoveries and initiatives [...]
The last few years have been a true revolution in terms of discoveries and initiatives [...]
Cancer cachexia is a complex metabolic syndrome characterized by marked loss of body weight, anorexia, [...]
Perhaps the definition is not the most accurate, but in reality a rare disease does [...]
In the last days of the year, it is time to review everything we have [...]
The Oligofastx project covers all areas, from start to finish, of the process of developing [...]
There is no doubt that oligonucleotide therapies aimed at providing answers and improving the quality [...]
A technological revolution can start with a key concept, the application of an equation or, [...]
The Oligofastx project covers the different phases of the development of oligonucleotide-based therapies, from design [...]
OLIGOFASTX follows with great interest all the recent advances in the work with oligonucleotides, not [...]
History is peppered with stories, legends and tales. And as in all of them, any [...]
Thyroid cancer is a common malignancy of the endocrine system. There are four types: Papillary [...]
Today we are going to talk about one of those diseases classified as rare, for [...]
The work of the most renowned scientists, artists and diplomats is rewarded every year at [...]
Every last Sunday of September is celebrated the International Retinitis Pigmentosa Day, one of the [...]
Today is International Myotonic Dystrophy Day, a rare disease with no treatment or cure to [...]
The project, subsidised by the CDTI with 5.4 million euros and a final budget of [...]